Sucampo’s new eye drops available in US

Sucampo Pharmaceuticals Inc. announced that Rescula eye drops have been launched in the U.S. market, according to a company press release.

The launch was made possible by a distribution partnership with R-Tech Ueno Ltd., a bioventure company that researches, develops and markets drugs, the release said.

The unoprostone isopropyl drops may be used as a first-line agent for the treatment of open-angle glaucoma or ocular hypertension. They may also be used concomitantly with other topical ophthalmic drug products that have an ocular hypotensive effect, according to the release.

Rescula function as a big potassium ion channel activator, which is different from other intraocular pressure-lowering agents, the release said.